Clinical trial
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
NCT05547737 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 21, 2022
- Completion date
- September 21, 2025
- Enrollment
- 500 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
nsclc